Etrumadenant

Generic Name: Etrumadenant

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₂N_₈O

CAS Number: 2239273-34-6

Unique Ingredient Identifier: W0ZE0NT8IF

Clinical Trials

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non Small Cell Lung Cancer
Non-small Cell Lung Cancer
Non-small Cell Carcinoma

Interventions: Drug: Zimberelimab
Drug: Domvanalimab
Drug: Etrumadenant

First Posted Date: 2021-03-10

Last Posted Date: 2025-05-11

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 30

Registration Number: NCT04791839

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Phase 1

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Etrumadenant
Drug: Regorafenib
Drug: AB680
Drug: Zimberelimab
Drug: Bevacizumab
Drug: m-FOLFOX-6 regimen

First Posted Date: 2020-12-09

Last Posted Date: 2025-05-08

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 227

Registration Number: NCT04660812

Locations: 🇫🇷
Clinique Sainte Anne, Strasbourg, France
🇮🇹
Ircc Istituto Per La Ricerca E La Cura Del Cancro Di Candiolo Oncologia Medica, Candiolo, Italy
🇮🇹
IRCCS - Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis, Castellana Grotte, Italy

and more 48 locations

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Androgen-Resistant Prostatic Neoplasms
Castration Resistant Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant
Prostatic Cancer, Castration-Resistant

Interventions: Drug: Etrumadenant
Drug: Zimberelimab
Drug: Quemliclustat
Drug: SG
Drug: Docetaxel
Drug: Enzalutamide

First Posted Date: 2020-05-11

Last Posted Date: 2024-06-03

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 173

Registration Number: NCT04381832

Locations: 🇺🇸
Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸
The Oncology Institute of Hope & Innovation, Cerritos, California, United States
🇺🇸
The University of California, Los Angeles, Encino, California, United States

and more 16 locations

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Squamous Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Lung Cancer
Nonsquamous Non Small Cell Lung Cancer

Interventions: Drug: Domvanalimab
Drug: Etrumadenant
Drug: Zimberelimab

First Posted Date: 2020-02-10

Last Posted Date: 2025-05-08

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 151

Registration Number: NCT04262856

Locations: 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
🇨🇳
Chi Mei Hospital, Tainan City, Taiwan
🇰🇷
Chungbuk National University Hospital (CBNUH), Cheongju, Korea, Republic of

and more 40 locations

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer
Nonsquamous Nonsmall Cell Neoplasm of Lung
Sensitizing EGFR Gene Mutation

Interventions: Drug: Etrumadenant
Drug: Zimberelimab
Drug: Carboplatin
Drug: Pemetrexed
Drug: Pembrolizumab

First Posted Date: 2019-02-19

Last Posted Date: 2024-12-09

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 77

Registration Number: NCT03846310

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
🇰🇷
Bundang CHA Medical Center, Seongnam-si, Korea, Republic of
🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

and more 19 locations

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Phase 2

Recruiting

Conditions: Localized Prostate Cancer
Prostate Cancer
Prostate Adenocarcinoma

Interventions: Drug: Atezolizumab
Drug: Etrumadenant
Drug: Tocilizumab

First Posted Date: 2019-01-29

Last Posted Date: 2025-05-15

Lead Sponsor: David Oh

Target Recruit Count: 68

Registration Number: NCT03821246

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Alvin J. Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Phase 1

Completed

Conditions: Colorectal Cancer
GastroEsophageal Cancer

Interventions: Drug: etrumadenant
Drug: mFOLFOX

First Posted Date: 2018-10-25

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 44

Registration Number: NCT03720678

Locations: 🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia

and more 21 locations

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1

Completed

Conditions: TNBC - Triple-Negative Breast Cancer
Ovarian Cancer

Interventions: Drug: Etrumadenant
Drug: nanoparticle albumin-bound paclitaxel (NP)
Drug: IPI-549
Drug: Pegylated liposomal doxorubicin (PLD)

First Posted Date: 2018-10-25

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 35

Registration Number: NCT03719326

Locations: 🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸
Texas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States

and more 24 locations

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck
Breast Cancer
Colorectal Cancer
Melanoma
Bladder Cancer
Ovarian Cancer
Endometrial Cancer
Merkel Cell Carcinoma
GastroEsophageal Cancer

Interventions: Drug: Etrumadenant
Drug: Zimberelimab

First Posted Date: 2018-08-14

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 48

Registration Number: NCT03629756

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇦🇺
Cabrini Health Limited, Malvern, Australia
🇺🇸
Scottsdale Healthcare Hospitals dba HonorHealth, Scottsdale, Arizona, United States

and more 12 locations

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Phase 1

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: Atezolizumab
Drug: Regorafenib
Genetic: LOAd703
Drug: Isatuximab
Drug: Idasanutlin
Drug: Imprime PGG
Drug: Bevacizumab
Drug: AB928
Drug: Selicrelumab

First Posted Date: 2018-06-13

Last Posted Date: 2023-11-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 96

Registration Number: NCT03555149

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy